Exclusive: Two ex-Recursion leaders start Noetik in a bid to fix the broken funnel in cancer drug research
Two former leaders of Recursion Pharmaceuticals have started their own biotech startup, hoping to bring a similar data-obsessed mentality to cancer research.
The San Francisco-based company called Noetik launched Thursday, announcing a $14 million seed round led by DCVC. Its two co-founders are CEO Ron Alfa, formerly head of research at Recursion, and CSO Jacob Rinaldi, who previously led oncology research at the Utah biotech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.